A Diffuse Large B-Cell Lymphoma Classification System That Associates Normal B-Cell Subset Phenotypes with Prognosis
Karen Dybkær(Aalborg University Hospital), Hans Erik Johnsen(Herlev Hospital), Ken H. Young(Duke Medical Center), Sara Correia Marques(Chr. Hansen (Denmark)), Rajen D. Shah(Chr. Hansen (Denmark)), Zijun Y. Xu‐Monette(Duke University), Kim Steve Bergkvist(Chr. Hansen (Denmark)), Tarec Christoffer El‐Galaly(Aalborg University Hospital), Mette Nyegaard(Statens Serum Institut), María Rodrigo-Domingo(Chr. Hansen (Denmark)), Alexander Schmitz(Chr. Hansen (Denmark)), Maria Bach Laursen(Chr. Hansen (Denmark)), Julie Støve Bødker(Chr. Hansen (Denmark)), Steffen Falgreen(Chr. Hansen (Denmark)), Martin Bøgsted(Chr. Hansen (Denmark)), Anders Ellern Bilgrau(Chr. Hansen (Denmark)), Preben Johansen(Chr. Hansen (Denmark)), Sophie Bech Rasmussen(Chr. Hansen (Denmark)), Michael Gaihede(Chr. Hansen (Denmark)), Ling Li(First People's Hospital of Nanning), Richard J. Samworth(University of Cambridge), Malene Krag Kjeldsen(Chr. Hansen (Denmark)), Michael Møller(Hospital South West Jutland)
Cited by 2
Related Papers
Common variants conferring risk of schizophrenia
|Nature|2009|1.7k
Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
|Journal of Clinical Oncology|2012|682
Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant–Associated Anaplastic Large-Cell Lymphoma
|Journal of Clinical Oncology|2015|418